NervGen Pharma Corp.
TSXV NGEN.V
NervGen Pharma Corp. Market Capitalization on January 14, 2025: USD 148.89 M
-
NervGen Pharma Corp. 52-week high Market Capitalization is USD 170.42 M on February 07, 2024, which is 14.46% above the current Market Capitalization.
-
NervGen Pharma Corp. 52-week low Market Capitalization is USD 78.93 M on June 05, 2024, which is -46.99% below the current Market Capitalization.
-
NervGen Pharma Corp. average Market Capitalization for the last 52 weeks is USD 119.01 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Mr. Michael Kelly |
| IPO Date | March 15, 2019 |
| Location | Canada |
| Headquarters | 2955 Virtual Way |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Past 5 years
USD 0.91
StockViz Staff
January 15, 2025
Any question? Send us an email